Thursday, 22 Jun 2017

You are here

Herpes Zoster

Today during the comorbidities in RA session, Dr. Leonard Calabrese spoke about herpes zoster (HZ). Given the frequency of HZ in immunocompetent persons and the fact that patients with IMIDs carry at least twice the risk of developing HZ, it is important for rheumatologists to be informed about diagnosis, treatment and most importantly prevention of HZ. We all can recognize the classic vesicular rash of HZ so diagnosis is often made clinically. However, there are cases when the diagnosis is not so clear, including during the prodromal phase, early rash that may resemble HSV infection, contact dermatitis or CA-MRSA, and cases of HZ sine herpete, which occurs ~2% of the time. 

Perhaps the most important reason why rheumatologists should be concerned about HZ is because of the complications, which are numerous and include post-herpetic neuralgia, motor neuropathy, cranial palsy, encephalitis, transverse myelitis and stroke. Numerous groups have recently reported the risk of stroke after HZ, in particular in the first 3 months following infection (Calabrese LH, et al. A&R 2017;69(2):439-46).


As far as treatment, we recommend that all immunocompromised hosts be treated with antivirals (acyclovir, valacyclovir, famciclovir) even if symptoms have been present for > 72 hours, as there is a low ratio of harm-to-benefit and treatment can decrease pain, promote healing and decrease shedding. It remains unclear whether or not antiviral treatment reduces risk of PHN. Complicated HZ (disseminated, CNS, visceral, opthalmic) requires hospital admission and IV antiviral therapy.

In terms of prevention, as Calabrese put it – “the best strategy for preventing complications of HZ is to prevent HZ”. While the live-attenuated herpes zoster vaccine (Zostavax) is contraindicated in the setting of most immunosuppression, the footnotes of the 2017 ACIP recommendations for vaccination state it can be given in the following instances: if not on a biologic, if taking the equivalent of prednisone 20 mg/d or less, or traditional doses if MTX or AZA. Regardless, our Zostavax administration rate remains ~ 5%. There are many reasons for this, including uncertainty of optimal timing, as vaccine efficacy wanes significantly after 5 years. At present time there is a HZ subunit vaccine in the late stages of clinical trials and the data look quite promising as far as duration of immunogenicity and efficacy in older adults (Cunningham AL, NEJM 2016;375:1019-32). Stay tuned.

 

 

Add new comment

More Like This

EULAR 2017 – Day 4 Highlights

Saturday was a day of big posters and special seminars at EULAR in Madrid.  In the morning, I passed on an interesting session on nailfold capillaroscopy led by Dr. M Cutolo and went to a JIA outcomes session. I reported on this in a video from day 4 (Saturday) called “Long-Term Comorbidities in JIA” – you can find it here.

Responder Criteria for Nonpharmalogical Treatment of Fibromyalgia.

Because of the subjective nature of fibromyalgia symptoms, tools for monitoring of disease activity and/or treatment assessment tools to evaluate effectiveness of nonpharmacological modalities are difficult to develop.

Concomitant Septic Arthritis and Crystalline Arthropathy

Researchers sought to describe the characteristics of patients with concurrent septic and crystal arthritis through a retrospective analysis of patients with the concomitant diagnoses between 1985-2015 at a university hospital in Spain.

EULAR 2017 – Day 3 Highlights

Friday was a mega-day in Madrid as this day all the late-breaking abstracts were presented, in addition to the bulk of high-impact podium presentations in several areas.

Here are the major presentations from several clinical areas.

Guselkumab for Active Psoriatic Arthritis

A double-blind, placebo-controlled, multicenter study aimed to evaluate efficacy and safety of a fully human monoclonal anti IL-23 antibody guselkumab, in patients with active psoriatic arthritis.